• BioAdaptives retired its largest convertible commercial investor, clearing outstanding convertible debt and removing related equity overhang.
• The move eliminates near-term dilution risk from conversions, easing selling pressure tied to the convertible instrument.
• The company framed the transaction as a shift toward non-dilutive funding ahead of the XcellaraHeart launch in August.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAdaptives Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607300830ACCESSWRNAPR_____1198703) on July 30, 2026, and is solely responsible for the information contained therein.